

**CERTIFICATE OF MAILING**

I hereby certify that this document is being deposited with the United States Postal Service as First Class mail in an envelope addressed: Commissioner for Patents, Washington, D.C. 20231, on the date noted below:

Date: November 15, 2002

Sean Mellino
Sean Mellino

RECEIVED
NOV 28 2002
TECH CENTER 1600/2300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Robert Peter Klein, et al.

Serial No. : 09/720,287 (Conf. No.: 1252)

Filed : May 10, 2001

Title : Transdermal Therapeutic System Containing
Hormones and Crystallization Inhibitors

Examiner : Isis Ghali

Art Unit : 1615

Attorney Docket : RO0208US (#90568)

Box Response – Fee
Commissioner for Patents
Washington D.C., 20231

MARKED UP PARAGRAPH

Example	Comp- arison	2	3	4	5	6	7
Durotak 387- 2287	424.31	132.8 4	162.2 5	171.5 0	171.5 0	162.2 5	171.5 0
Oestradiol hemihydrate	3.37	1.34	1.34	1.34	1.34	1.34	1.34
Norethister- one acetate	21.60	8.65	8.65	8.65	8.65	8.65	8.65
Eutanol G	5.59	2.25	2.25	2.25	2.25	2.25	2.25
Al acetyl- acetate	1.36	0.054	0.054	0.054	0.054	0.054	0.054
Ethyl acetate		36.48	29.28	27.11	27.11	29.28	27.11
Ethanol		36.48	29.28	27.11	27.11	29.28	27.11
Methyl ethyl ketone	134.79	--	--	--	--	--	--
[Euredur]	--	20.0	--	--	--	--	--

EUREDUR 145 - A curing agent for epoxide resins						
[Euredur] EUREDUR 125 - A curing agent for epoxide resins	--	--	5.0	--	--	--
[Euredur] EUREDUR 250 - A curing agent for epoxide resins	--	--	--	0.5	--	--
[Euredur] EUREDUR 43 - - A curing agent for epoxide resins	--	--	--	--	0.5	--
[Euredur] EUREDUR 27 - - A curing agent for epoxide resins	--	--	--	--	--	5.0
[Euredur] EUREDUR 10 - - A curing agent for epoxide resins	--	--	--	--	--	0.5

* * *



CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service as First Class mail in an envelope addressed: Commissioner for Patents, Washington, D.C. 20231, on the date noted below:

Date: November 15, 2002

Sean Mellino
Sean Mellino

RECEIVED
NOV 22 2002
TECH CENTER 1600 2300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Robert Peter Klein, et al.
Serial No. : 09/720,287 (Conf. No.: 1252)
Filed : May 10, 2001
Title : Transdermal Therapeutic System Containing
Hormones and Crystallization Inhibitors
Examiner : Isis Ghali
Art Unit : 1615
Attorney Docket : RO0208US (#90568)
Box Response – Fee
Commissioner for Patents
Washington D.C., 20231

MARKED UP CLAIMS

1. (Twice amended) A transdermal [Transdermal] therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising:
a backing layer[.]; and
a reservoir supersaturated with active ingredients and containing oestradiol and norethisterone acetate, said reservoir is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors[.]; and is a detachable protective layer, wherein the crystallization inhibitor is an amino group-containing polymer selected from the group consisting of polyaminoamides,

polyaminoimidazolines, polyetherurethaneamines, polyamines, polyglucosamines and a copolymer based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate being present in a molar ratio of 1:2:1 (butyl methacrylate : 2-dimethylaminoethyl methacrylate : methyl methacrylate).

3. (Twice amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 1, wherein the reservoir comprises at least one crystallization inhibitor in proportion of from 0.05 to 30% by weight.

4. (Twice amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 1, wherein the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, and in an overall concentration of up to 25% by weight.

5. (Twice amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 1, wherein the reservoir includes a constituent from the group consisting of [ageing] aging inhibitors, plasticizers, antioxidants and absorption improvers, the plasticizers being used in a concentration of 0 [-] to 5% by weight and the [ageing] aging inhibitor in a concentration of 0.1 [-] to 2% by weight.

6. (Twice amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 1, wherein the pressure-sensitive adhesive is selected from the group consisting of a solvent-based adhesive, a dispersion adhesive, a hot-melt adhesive and a UV-crosslinkable adhesive.

7. (Twice amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 1, wherein the reservoir consists of at least two layers.

8. (Twice amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 1, wherein the reservoir has a layer thickness of 0.02 mm to 0.500 mm.

9. (Twice amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 1, wherein the reservoir is provided with an additional pressure-sensitive adhesive layer.

11. (Amended) A transdermal [Transdermal] therapeutic system according to claim 4, wherein the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:3 to 1:7.

12. (Amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 8, wherein the reservoir has a layer thickness of 0.030 [–] to 0.200 mm.

13. (Amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 9, wherein the reservoir is provided with a pressure-sensitive adhesive margin.

14. (Amended) A transdermal [Transdermal] therapeutic system according to claim [Claim] 1, wherein the reservoir is provided with a pressure-sensitive adhesive margin.

15. (Amended) A method for providing a transdermal therapeutic system for therapeutic applications in human medicine, said method comprising:

applying said transdermal therapeutic system to the skin of a patient by applying a polyacrylate pressure- sensitive adhesive to said transdermal therapeutic system; and

controlling the release of oestradiol in combination with norethisterone acetate to the human skin by providing a reservoir in said transdermal therapeutic system, said reservoir being supersaturated with active ingredients and being attached to a backing layer, wherein said reservoir comprises at least one amino group-containing polymer and at least one adhesive selected from the group consisting of a polyacrylate pressure-sensitive adhesive layer and a pressure-sensitive adhesive margin.